Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra.
Bryan K. Yamamoto, J F Nash, Gary A. Gudelsky
Journal of Pharmacology and Experimental Therapeutics June 1, 1995 DOI: 10.1016/s0022-3565(25)09555-2 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental animal study using in vivo microdialysis Peer reviewed |
|---|---|
| Population | Awake rats (Sprague-Dawley) |
| Interventions | MDMA d-amphetamine ritanserin |
| Measures | in vivo microdialysis |
| Topics | Serotonin MDMA |
| Keywords | Substantia nigra Corpus striatum Animals Rats, sprague-dawley Dextroamphetamine N-methyl-3,4-methylenedioxyamphetamine Gamma-aminobutyric acid Tetrodotoxin Male |
| Key findings | MDMA increased striatal dopamine release partly through an impulse-mediated mechanism, since tetrodotoxin infusion into the striatum attenuated the increase. Ritanserin, a 5-HT2A/2C antagonist, infused into either the striatum or substantia nigra also reduced MDMA-induced striatal dopamine release. At the doses used, MDMA but not d-amphetamine raised 5-HT and decreased GABA efflux in the substantia nigra, and ritanserin blocked this GABA decrease, indicating regulation by 5-HT2A/2C receptors and GABAergic input. |
Abstract
The effects of the amphetamine analog, 3,4-methylenedioxymethamphetamine (MDMA) were compared to the effects of d-amphetamine on the in vivo release of dopamine and gamma-aminobutyric acid (GABA) in the striatum and substantia nigra. The brain region-dependent role of the 5-HT2 receptors in the striatum and substantia nigra in regulating MDMA-induced dopamine and GABA release also was studied. Changes in the extracellular concentration of dopamine, 5-HT and GABA were measured simultaneously in the awake rat by in vivo microdialysis. The increase in striatal dopamine produced by systemic administration of MDMA was attenuated by infusion of TTX into the striatum. Infusion of the 5-HT2A/2C antagonist ritanserin into the striatum or the ipsilateral substantia nigra also significantly attenuated MDMA-induced dopamine release in the striatum. At the doses used in this study, MDMA but not d-amphetamine increased the extracellular concentrations of 5-HT and decreased GABA efflux in the substantia nigra. The ability of MDMA to decrease nigral GABA efflux also was blocked by the local infusion of ritanserin into either the substantia nigra or the striatum. Overall, these data provide evidence that MDMA increases dopamine release partly through an impulse-mediated mechanism. Furthermore, this increase in striatal dopamine efflux produced by MDMA is regulated, in part, by 5-HT2A/2C receptors in the striatum and the substantia nigra and ultimately by GABAergic input into the substantia nigra.
Comparable studies
Other preclinical and animal studies on MDMA, most cited first.
Citations in the library
Cited by 39
- 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings Psychopharmacology March 15, 2006
- Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms Pharmacological Reviews December 16, 2020
- Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA) Psychopharmacology July 24, 2017
- Acute Psychological and Neurophysiological Effects of MDMA in Humans Journal of Psychoactive Drugs June 1, 2002
- Serotonin–GABA interactions modulate MDMA‐induced mesolimbic dopamine release Journal of Neurochemistry October 27, 2004
and 34 more in the library